NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoring

PUBT · 1d ago
NeoGenomics RaDaR ST gains expanded Medicare coverage for immunotherapy response monitoring
  • NeoGenomics secured expanded Medicare coverage from CMS MolDX for its RaDaR ST MRD assay to monitor immunotherapy response in late-stage solid tumors.
  • The decision adds a third Medicare-covered indication for RaDaR ST, broadening reimbursement for longitudinal treatment-response monitoring.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260826891210) on August 26, 2026, and is solely responsible for the information contained therein.